Market Trends– category –
-
Genprex Taps Andelyn Biosciences to Accelerate Manufacturing Scale-Up for Diabetes Gene Therapy Program
Contract Pharma USA Overview Clinical-stage company Genprex has selected Andelyn Biosciences as its CDMO to scale up manufacturing for its diabetes gene therapy program. Leveraging its proprietary Curator Cell and Gene Therapy Platform, ... -
Cell Therapy Market Sees 26% Revenue Growth, Driven by Commercial Successes and Strategic Investment in Scalable Manufacturing
New Market Pitch Unknown Overview The cell therapy market is experiencing robust growth, with key commercial products reporting approximately 26% year-over-year revenue increase. Carvykti, for instance, treated over 10,000 clinical and c... -
Century Therapeutics Seeks Director to Lead Large-Scale Cell Therapy Process Development for Clinical and Commercial Programs
JobLeads (Century Therapeutics, Inc.) USA Overview Century Therapeutics is recruiting a Director of Large-Scale Process Development to lead scale-up strategies for bioreactor expansion, harvesting, and fill/finish operations in their cli... -
Cell and Gene Therapy Sector Shifts to “Execution Discipline” Amidst Manufacturing Platform Scrutiny and Autoimmune CAR-T Safety Concerns
LucidQuest Ventures USA Overview A recent strategic roundup highlights a critical shift in the cell and gene therapy (CGT) sector from platform expansion to "execution discipline," emphasized by Bristol Myers Squibb's termination of its ... -
Panasonic and Kyoto University CiRA Foundation Develop Fully Automated iPSC Establishment System to Accelerate Regenerative Medicine Adoption
Panasonic Holdings (Facebook post) Japan Overview Panasonic Holdings and the Kyoto University iPS Cell Research Institute (CiRA) Foundation have collaboratively developed a groundbreaking automated system for establishing iPS cells from ... -
Northway Biotech Inaugurates €61 Million Cell Therapy CDMO Facility in Vilnius, First in the Baltics
PR Newswire Lithuania Overview Northway Biotech has invested €61 million to establish the Baltic states' first large-scale Contract Development and Manufacturing Organization (CDMO) facility for cell therapy and personalized medicine in ... -
Hereditary Transthyretin Amyloidosis Market: Intellia/Regeneron’s CRISPR Gene Editor Nexiguran ziclumeran Receives FDA RMAT Designation
GlobeNewswire USA Overview This article summarizes a market research report by DelveInsight on the hereditary transthyretin amyloidosis (hATTR) market. The report highlights Nexiguran ziclumeran (nex-z), a CRISPR-Cas9-based gene-editing ... -
ARPA-H Invests $125M in On-Demand RNA Medicine Manufacturing; ArsenalBio Pivots to In Vivo CAR T Cell Therapies for Solid Tumors
The Pharma Letter USA Overview ARPA-H has committed $125 million to five teams developing on-demand manufacturing capabilities for RNA medicines, a strategic investment to enhance rapid pharmaceutical response to future public health cri... -
AI Data Center Boom Hits Power and Cooling Supply Bottlenecks, Accelerating Liquid Cooling Adoption to 70% by 2030
Reuters Global Overview Intensifying AI competition is causing unexpected supply chain bottlenecks in power and cooling systems for data centers, struggling to keep pace with demanding servers. Demand for transformers, generators, power ... -
Dragonfly Acquires Modern Data Stack to Boost AI Intelligence Platform Capabilities
SaaS M&A and VC Deals USA Overview Dragonfly, an AI-powered technology intelligence platform, has announced the acquisition of Modern Data Stack (MDS). This acquisition will allow Dragonfly to leverage MDS's extensive directory of over 5...
